MedPath logo

VYNDAMAX SOFT GELATIN CAPSULE 61MG

Prescription Only
Drug type: Therapeutic
ATC code: N07XX08
Dosage form: CAPSULE
Route of administration: ORAL
Active ingredient: Tafamidis; TAFAMIDIS

4.1 Therapeutic indications

VYNDAQEL/VYNDAMAX is indicated for the treatment of transthyretin amyloidosis in adult patients with wild-type or hereditary cardiomyopathy to reduce all-cause mortality and cardiovascular-related hospitalisation.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients of VYNDAQEL/VYNDAMAX (see Section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

4.2 Posology and method of administration

Posology

The recommended dose of VYNDAQEL/VYNDAMAX is 61 mg tafamidis orally once daily (see Section 5.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) or 80 mg tafamidis meglumine (administered as four 20 mg capsules) once daily.

VYNDAQEL/VYNDAMAX can be taken with or without food.

A single 61 mg tafamidis capsule is bioequivalent to 80 mg tafamidis meglumine (four 20 mg tafamidis meglumine capsules). The two formulations are not interchangeable on a per mg basis (see Sections 5.1 and 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Special populations

Paediatric

VYNDAQEL/VYNDAMAX should not be prescribed in the paediatric population as transthyretin amyloidosis is not a disease present in this population.

Elderly

No dosage adjustment is required for elderly patients (≥65 years) (see Section 5.2 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Renal or hepatic impairment

No dosage adjustment is required for patients with renal impairment, or mild or moderate hepatic impairment. VYNDAQEL/VYNDAMAX has not been studied in patients with severe hepatic impairment.

Method of administration

Oral use.

The capsule(s) should be swallowed whole and not crushed or cut. VYNDAQEL/VYNDAMAX may be taken with or without food.

If a dose is missed, the patient should take the dose as soon as remembered. If it is almost time for the next dose, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose.

Registrant
PFIZER PRIVATE LIMITED
Approval Date
2020-02-27
Approval Number
SIN15894P
Manufacturer
Catalent Pharma Solutions AndersonBrecon Inc. (Primary packager)
Licence Holder
PFIZER PRIVATE LIMITED